Ibrutinib
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lymphoma, B-Cell
Conditions
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
Trial Timeline
May 22, 2017 → May 10, 2027
NCT ID
NCT03229200About Ibrutinib
Ibrutinib is a approved stage product being developed by Johnson & Johnson for Lymphoma, B-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT03229200. Target conditions include Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell.
What happened to similar drugs?
17 of 20 similar drugs in Lymphoma, B-Cell were approved
Approved (17) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03476655 | Pre-clinical | Completed |
| NCT03229200 | Approved | Active |
Competing Products
20 competing products in Lymphoma, B-Cell